"The need for better single-use and disposable systems in downstream processing is growing…The move toward disposable upstream bioprocessing will push downstream operations toward innovative alternatives that may include membrane adsorbers and prepacked single-use chromatography columns."
"Disposable Chromatography: Options Are Increasing" Genetic Engineering News, Dec. 10, 2013
CHRETO TechnologyTM process overview illustrating the catch, clean and collect steps. See details below (How does it work?).
The characteristics of the DAP molecule include 1) easy elution and no leakage, 2) specific binding to product (to secure selective reaction with target protein(s) and easy dissolving of formed DAP-target complexes and 3) tight binding to solid support (to secure immobilization and final removal of DAP molecules from product stream)
The purification process consists of three steps: catch, clean and collect.
The left-hand figure (above) shows the chromatogram profile, with two major protein peaks representing the fractions containing the flow through after reaction with DAP (Fraction 7 and Lane 7 on the SDS gel, right panel above), and the fraction containing the purified mAb (Fraction 8 and Lane 8 on the SDS gel above). Lane 3 shows purified DAP; Lane 4 shows the feedstock used and Lane 6 show the same sample run without addition of DAP. Lanes 1 and 10 include the MW marker.
The left-hand figure (above) shows the chromatogram profile, with three major protein peaks representing, from left to right: proteins not bound to DAP, proteins washed away from DAP-target complexes and the elution of the DAP-purified IVIG, respectively. Arrows indicate the fractions that are further analysed by SDS-PAGE (figure on the right). Lanes 7-9 on the SDS-PAGE contain highly purified gamma globulins (right-hand panel above).
High purity was obtained using a single purification step for both mAb purification and plasma fractionation.
Board of Directors
Lars Bäckman - Chairman of the board
Lars Bäckman holds the position as VP of Corporate Development with Biotage AB since January 2007 and he is also the General Manager of Biotage subsidiary MIP Technologies. Prior joining Biotage, Lars Bäckman held the position as SVP of Corporate Development at Affibody. He has previous experiences acting as a lawyer at the Swedish law firm Hamilton & Co, specialized in Corporate Finance and Mergers & Acquisitions, and from Venture Management at the Business Development firm Googol. Mr. Bäckman holds a LLM from the Stockholm University and was born in 1961.
Kim Bjørnstrup - Member of the board
Kim has a management carrier of more than 25 years in the pharmaceutical industry. He graduated from Copenhagen University in 1984 and was licensed as a Lawyer in 1987.
From 1987 to 1992, he was Internal Legal Counsel to Lundbeck AS and Later Coloplast AS.
From 1992 to 2010 he worked at Octapharma AG in Switzerland, a swiss biotech, initially as Licensing manager and the last 10 years Vice Chairman /CEO. The Company had revenues exceeding one billion EURO and 4000 employees.
In 2010, he re-started Xeltis AG a Swiss biotech with a group of investors, specialising in self-generating heart valves.
From 2013 to 2014, he was the CEO of BPL UK a company with revenues of 300 million EURO and 2000 employees.
From 2015 he worked as CEO at Assistance HR Partners AS, where he I s co-owner, a company specialising in management training recruitment and temporary work.
Mikael Bundgaard-Nielsen - Member of the board
Mikael Bundgaard-Nielsen holds a position as VP for Product & Process Development with Novozymes A/S since 2013. Prior to this position Mr. Bundgaard-Nielsen (2008-2012) was Managing Director for Novozymes Biopharma Sweden AB (now Repligen Sweden AB) in Lund, that manufactures affinity ligands and active pharmaceutical ingredients according to cGMP. He has additional experience
from various leadership positions within research, development and manufacturing in Novo Nordisk A/S, Pharmexa A/S and
Mr. Bundgaard-Nielsen holds a Master of Science in Chemical Engineering and a Graduate Diploma in Business Administration. He was born 1969.
Sussi Wetterlin - Member of the board
Sussi is CEO of BASTAonline, a company focused on the substitution of chemicals of concern in the Building and Construction sector.
Sussi has more than 20 years of experience from the chemical industry within the environmental and commercial area. Sussi has extensive managerial experience with proven track record of leading international sales organisations during build-up, growth and turnaround phases. She held a position as European Sales Director in the Wood Industry sector with focus on the emerging markets in Eastern Europe and Russia.
Sussi has a M.Sc in Toxicology from Karolinska Institutet in Stockholm
Svend Licht - Member of the board
Svend is Chief Commercial Officer in Albumedix A/S, with responsibility for commerical activities, customer technical support, IP, regulatory and legal matters.
Svend brings more than 25 years managerial experience from international positions in Sales, Marketing, Business Development and M&A. His broad professional background and strong business skills have previously been utilized in companies such as Novo Nordisk and Novozymes through various positions, most recently as Global Head of Sales & Business Development in Novozymes Biopharma. Svend Erik Licht also serves on a number of life science boards.
Svend holds a B.Sc. in chemical engineering from the Technical University of Denmark, a B.Sc. in foreign trade from Copenhagen Business School and an executive MBA with distinction from Ashridge Management College in UK.
Click on the names to see CV
Jan Kyhse-Andersen - Chief Executive Officer
Jan is inventor of the DAP technology and founder of CHRETO. Jan has more than 25 years entrepreneurial and managerial experience from the biotechnology and diagnostic industry. Jan held a position as senior manager in Business Development at Novozymes A/S, prior to the management spin-out of the DAP technology. Jan has been supervisory Board Member in a privately equity fund, Life Equity Sweden KB for several years and prior to joining Novozymes A/S, Jan was Vice President, R&D and Production at Vir Biosensors A/S (SPR biosensor).
Jan started his career as post doc at the Technical University of Denmark and then joined DAKO A/S where he had several managerial positions in Diagnostic assay development, Sales and Marketing, R&D manager and subsequently Director of Antibody Manufacturing.
Jan is also the inventor of Semi Dry Electroblotting, which significantly improved the Western blotting procedure. Jan was founder of JKA-BIOTECH and co-founder of Kem-En-Tec A/S and was the first to commercialize the Semi Drying Electroblotting apparatus.
Jan holds a M.Sc. and a Ph.D. in Chemical Engineering from Technology University of Denmark.
Click on the names to see CV
Get in touch with us to hear more about DAP technology and its exciting potential for the biopharmaceutical and plasma fractionation industries.
Tel: +45 22 92 80 82
Scan to call directly
Scan to send an Email
CHRETO :: Lejrvej 17 :: DK-3500 Værløse :: Denmark :: tel: +45 22 92 80 82 :: Email: email@example.com